Presented at the World Vaccine Congress 2026: Extracellular Secretion and Non-canonical Amino Acid (ncAA) Incorporation: New Capabilities Supporting Conjugate Vaccine Discovery and Development

Presented at the World Vaccine Congress 2026: Extracellular Secretion and Non-canonical Amino Acid (ncAA) Incorporation: New Capabilities Supporting Conjugate Vaccine Discovery and Development

ABSTRACT: Efficient production of vaccine carrier proteins and antigens is paramount to ensuring access to affordable conjugate vaccines. Streamlined conjugation technologies improve product quality and consistency and allow lower antigen input needs. Development of...
Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity

Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity

ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs As an example of the workflow, an Anti-GPCR VHH therapeutic candidate modified to include a single ncAA...
Presented at Antibody Engineering & Therapeutics US 2025: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity

Presented at Antibody Engineering & Therapeutics US 2025: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity

ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs. As an example of the workflow, an Anti-GPCR VHH therapeutic candidate modified to include a single ncAA...